. The mechanism by which HIV infection increases the risk of CVD is not fully known. Possible mechanisms increasing the risk of CVD involve chronic inflammation (6, 7) , immune dysregulation (8) , metabolic changes (9) , increased coagulation (10), dyslipidemia (11) , and endothelial dysfunction (12) . Data from our group and others have demonstrated that platelets in persons with HIV reveal a basally activated state, which suggests that pathological platelet activation may contribute to HIV-mediated CVD (13) (14) (15) (16) ).
Platelets play a major role in hemostasis, with increased platelet activity contributing to the pathogenesis of atherothrombosis (17) . In addition to their well-known functions in hemostasis and thrombosis, platelets play an important role in inflammation and immune activation (18) . Activated platelets synthesize and release a host of pleiotropic inflammatory mediators, including interleukin-1b, CD40L, microparticles, and tissue factor, which interact with leukocytes and endothelial cells (19) (20) (21) (22) . Platelets are discoid, anucleate cells generated from bone marrow megakaryocytes that retain megakaryocyte-derived mRNAs and translational machinery for protein biosynthesis (23) (24) (25) . Platelet RNA expression profiling has been used in subjects with sickle cell disease, obesity, systemic lupus erythematosus, and CVD (26) (27) (28) (29) (30) . Transcriptional profiling may yield novel mechanistic insights, unbiased by pre-existing disease hypotheses.
We recently found the platelet transcriptome can: 1) distinguish healthy subjects with hyperreactive versus hyporeactive platelets; and 2) support a mechanistic link between platelet activity and CVD (31) .
In the present study, we performed unbiased transcriptome profiling in platelets from subjects with HIV under ART and healthy controls. The platelet transcriptome was analyzed and singletranscript models constructed to identify candidate mRNAs with differential expression. We then sought to validate and study the mechanism of our top candidate transcript using ex vivo and in vitro cellular and molecular assays. Marcantoni et al. Nearly 82% of the population was black, and 57%
were men. Fifty percent were current smokers. Mean Marcantoni et al.
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platelet activation on endothelial cells and monocytic cell line because these cell types play important roles in CVD pathogenesis (35, 36) . Labeled platelets isolated from HIV and healthy individuals were cocultured with HUVECs for 2 h in unstimulated (basal)
conditions and following incubation with thrombin (0.05 U/ml). In healthy subjects, few unstimulated platelets adhered to HUVECs ( Figure 1A) . By contrast, platelets in their basal state isolated from subjects with HIV had increased adhesion to endothelial cells ( Figure 1A) . Thrombin stimulation further increased platelet adhesion in both groups, with a more pronounced effect in the HIV group ( Figure 1A) .
Moreover, we observed that thrombin-activated platelets from subjects with HIV surrounded
HUVECs forming rosette-like aggregates ( Figure 1A) . Marcantoni et al.
genes between the 2 cohorts is reported in Figure 2B .
Using filtering criteria of a p value <0.01, GO analysis was performed on 73 differentially expressed transcripts (Supplemental Table 3 ).
Platelets from persons with HIV had increased expression of genes involved in secretion and exocytosis and leukocyte activation in immune responses ( Figure 2C , Supplemental Table 3 Table 4 ). No significant difference in ABCC4 expression was noted for hepatitis B, hepatitis C, CD4 count, smoking status, HIV duration, or type of ART (Supplemental Table 3 ). After adjustment for age, sex, race/ethnicity, and body mass index, persons with HIV had significantly higher ABCC4 than controls (b ¼ À2.9; p ¼ 0.001) (Supplemental Table 5 ).
Because platelet activity is increased in persons with HIV, we examined whether expression of platelet ABCC4 mRNA was associated with platelet activity. Platelet surface expression of P-selectin Figure 3A) . Immunofluorescence microscopy of collagen-spread platelets further confirmed increased ABCC4 expression in platelets isolated from subjects with HIV ( Figure 3B ).
ABCC4 INHIBITION REDUCES PLATELET GRANULE RELEASE AND IMPAIRS CYCLIC NUCLEOTIDE HOMEOSTASIS IN
HIV. Because ABCC4 is involved in the transport of diverse endogenous compounds, including dense granule content, we sought to investigate dense granule release in controls and HIV-infected subjects.
Accumulation of the fluorescent mepacrine is used as a dense granule marker (42, 43) . (47) (48) (49) . Platelets release S1P upon activation, and ABCC4 has been reported to mediate its release from platelets (50) . We therefore sought to investigate whether platelets from HIV-infected subjects with ABCC4 overexpression released greater amount of S1P compared with controls. In the basal state, S1P levels were markedly increased in HIV platelet supernatants ( Figure 5D ). After platelet activation, S1P
increased in both groups ( Figure 5E ). To confirm whether ABCC4 inhibition affects S1P levels, we measured S1P release in supernatants of Ceefourinpre-treated platelets. ABCC4 inhibition significantly reduced S1P levels following platelet activation ( Figure 5F ). Finally, S1P was measured in plasma of HIV and controls. S1P levels were significantly increased in plasma of subjects with HIV (p < 0.0001) ( Figure 5G ). Marcantoni et al. (16, 52 ). In the current study, we expand on these findings and demonstrate an enhanced platelet effector role in subjects with HIV.
Both in the basal state and following agonist stimulation, platelets from subjects with HIV were more adherent to endothelial cells and monocytic cells and were able to induce a proinflammatory effect on these cell types. These findings support the ABCC4 has been shown to play an important role in conveying several molecules that control multiple We and others have previously noted that platelet activity is in a heightened state in persons with HIV on ART (16, 52, 62, 63) . It was therefore not surprising that ABCC4 overexpression in HIV significantly correlated with platelet activation markers P-selectin and PAC-1, supporting a link between ABCC4 and platelet activity in these persons.
Localization of ABCC4 in platelets has been debated and remains uncertain. ABCC4 was demonstrated to be highly expressed on the membrane of dense granules, which facilitates ADP accumulation and export (42, 46) . It was also proposed that ABCC4 localization in platelets can be shifted from granules to the plasma membrane in certain high-risk conditions, including platelet activation (45, 64) . Other groups found that ABCC4 is localized primarily to the plasma membrane in platelets (65, 66) . We investigated dense granule ADP accumulation and release in HIV-infected subjects and healthy controls. We confirmed enhanced platelet activity in HIV-infected individuals, compared with controls in the basal state. The export of ADP and granule mediators was evaluated in both groups using the highly selective ABCC4 inhibitor, Ceefourin 2 (32).
In previous reports, ABCC4 platelet inhibition used the MK571 antagonist (65, 67, 68) . However, MK571 has been noted to be a non-specific ABCC4 inhibitor as well as a potent leukotriene D4 receptor and MRP1 antagonist (69) . In persons with HIV infection, Ceefourin inhibited dense granule release after thrombin activation, suggesting that ABCC4 impairs dense-granule release in HIV.
ABCC4 has been reported to be an endogenous regulator of intracellular cAMP and cAMP-mediated signaling pathway in platelets (44, 65, 68) . ABCC4 inhibition was found to protect from hypoxemia-induced pulmonary hypertension in a murine model by increasing intracellular cAMP levels and preventing activation of cAMP-mediated pathways (68) . In murine platelets, absence of ABCC4 attenuated collagenmediated aggregation and impaired thrombus formation by producing an elevation in cAMP level (65) .
Therefore, we sought to investigate whether ABCC4 modulated platelet activation in HIV through a cAMPmediated mechanism. We measured platelet cAMP secretion and cAMP cytosolic levels through VASP phosphorylation on Ser157. Our data demonstrated that platelet ABCC4 is an important contributor to platelet activity in HIV, by impairing cAMP homeostasis.
We then demonstrated that ABCC4 inhibition in platelets attenuated endothelial cell and monocyte activation, both in the basal state and after activation.
These data support a new role for platelet ABCC4 in mediating, not only platelet function, but also the platelet-mediated effector cell function in HIV. The mechanism linking platelet ABCC4 expression and monocyte/endothelial cell activation is unknown, but signaling lipid S1P is a likely intermediary. Platelets are known to release high levels of a multifunctional S1P upon direct activation of protein kinase C signaling (e.g., thrombin) or during blood clotting (70, 71) .
Cellular S1P secretion requires active transport across the membrane by ATP-dependent carriers, such as ABCC4 (50) . A link between platelet S1P in inflammatory processes and immune response has already been suggested (48, 72, 73) . In our study, we demonstrated an enhanced basal secretion of S1P from platelets in HIV, consistent with a hyperreactive platelet phenotype in the basal state. Moreover, ABCC4 inhibition was able to reduce S1P levels following thrombin- 
